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ABSTRACT 
Glucocorticoids (GCs) play important roles in many biological processes including 
inflammatory responses. The study of this process has involved investigations of cross-talk 
abilities by GC receptor (GR) with cellular signaling pathways that have been associated with 
inflammatory disorders or implicated as contributory for the adverse effects observed with GC 
therapy. This thesis aims to provide additional insights into this area of research and contains 
studies made to investigate aspects of GC-cross-talk with some of these signaling pathways, in 
particular the MAPK, NF-κB and Wnt signaling pathways. 
 MKP-1, an anti-inflammatory feed-back inhibitor of MAPK-signaling, has also 
been shown to be up-regulated by GCs. In paper I, we demonstrate that GCs stimulate 
expression of MKP-1 through a positive “tethering” mechanism involving the GR and the 
promoter-bound transcription factor C/EBP, without GR itself contacting the DNA. This study 
emphasizes the multiple mechanisms that exist by which agonist-bound GR can affect gene 
expression, also in the anti-inflammatory response. 
 GR mutants are powerful investigative tools that can be used to study cross-talk 
between GCs and the pro-inflammatory canonical NF-κB pathway. In paper II, we 
demonstrate that a “loss of function” GR mutant is able to repress NF-κB activated by TNFα, 
but not by TPA, whereas the wild-type receptor inhibits NF-κB in both cases. This study 
highlights that the ability of the GR to repress NF-κB not only relies on gene and cell context 
but also depends on the signaling pathway that is employed to activate NF-κB. 
 The non-canonical NF-κB pathway is emerging as a key player in various 
inflammatory diseases, but a cross-talk between this pathway and GCs have not been described.  
In paper III, we demonstrate for that GCs inhibit non-canonical NF-κB signaling and that the 
GR physically interacts with RelB and inhibits the transcriptional activity of RelB/p52 
heterodimers in a hormone-dependent manner.  
GC-induced hippocampal damage and osteoporosis have been suggested to be 
caused by the inhibition of the Wnt-signaling pathway by GCs. In paper IV, we demonstrate 
that GC stimulation of DKK-1, a Wnt-antagonist, inhibits proliferation of neuronal progenitor 
cells. The agonist-bound GR binds to a GRE in the regulatory promoter region of the DKK-1 
gene and induces its expression. Restoring the activity of Wnt-pathways that are inhibited by 
GCs may be valuable to limit some of the side-effects observed with GC therapy. 
In conclusion, the studies in this thesis give additional insight into the 
complexity, reciprocity and variety of cross-talk mechanisms involving GR and several 
signaling pathways, thereby providing an increased understanding of the molecular mechanisms 
behind GC effects with emphasis on their anti-inflammatory actions.  
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1 BACKGROUND 
 
In 1948 the therapeutic effects of glucocorticoids (GCs) were discovered when 
Compound E (later named cortisone) was successfully tested on arthritic patients. The 
impact of this event in the history of modern medicine has been profound (1). Due to 
their powerful ability to weaken the activity of the immune system and dampen 
inflammatory responses, cortisone and other GC equivalents have been extended to 
treat a wide spread of chronic inflammatory conditions. Today, exogenous GCs are the 
most commonly used drugs to treat autoimmune disorders, including rheumatoid 
arthritis, systemic lupus erythematosus, multiple sclerosis, inflammatory bowel disease, 
respiratory disorders such as asthma and chronic obstructive pulmonary disease, sepsis 
and multiple hypersensitivity and allergic reactions (2, 3). In addition to inflammatory 
diseases, GCs are commonly used for their immunosuppressive properties in 
transplantation, and for their anti-proliferative effects in lymphoid malignancies. 
However, prolonged use of GCs for therapeutic purposes has since the initial 
implementation been associated with multiple crippling side effects that significantly 
limits GC employment in the clinic. Osteoporosis is one of the most disabling side 
effects observed with long-term use of GCs, which leads to an increased fracture risk of 
the spine, hips and ribs (4). Other side effects accompanied with GC therapy include 
diabetes mellitus, hypertension, affective disorders, impaired wound healing, skin 
atrophy, central obesity and muscle wasting (5). Also, as a consequence of GCs 
immunosuppressive activity, immunodeficiency and increased sensitivity to pathogenic 
infections is a vital concern with long-term GC therapy. Indeed, even after more than 
half a century, the clinical use and potential for misuse of GCs is a matter of debate but 
despite the problems associated with their long-term use, GCs still remain the mainstay 
treatment of multiple inflammatory conditions (6). In addition, GC-resistance, 
characterized by either a progressive, partial or complete inability of inflamed tissues to 
respond to GCs, represents additional problems in current treatment of immune 
disorders such as asthma, inflammatory bowel disease and multiple sclerosis (2). The 
obstacles connected to GC therapy need to be overcome in order to improve the 
specificity and safety of GCs in the clinic. For this purpose, attention has for a long 
time been focused on elucidating aspects important for the biological effects of GCs 
such as regulation of inflammatory responses at the molecular level. This has involved, 
among many things, the study of GC receptor (GR) interactions or “cross-talk” with 
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cellular signaling pathways that have been implicated in the pathology of inflammatory 
disorders (such as NF-κB and MAPK signaling pathways) or implicated as contributory 
for the adverse effects observed with GC therapy (e.g. metabolic and Wnt signaling 
pathways). This work contains studies (Paper I-IV) made to address aspects of the 
cross-talk ability of GR with some of these signaling pathways and presents some new 
findings in this area of research. 
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2 INTRODUCTION 
 
2.1 GLUCOCORTICOID SIGNALING 
 
2.1.1 Glucocorticoids and their functions 
GCs are small fat-soluble steroid hormones produced from the adrenal cortex of 
vertebrates that influence the functions of basically all organs and tissues throughout 
life, with key roles in a broad range of biological processes, including metabolism, 
immune responses, growth, development, differentiation and apoptosis (2, 7). GCs, in 
humans mainly cortisol, are the secreted end-effectors of the hypothalamic-pituitary-
adrenal (HPA) axis, which is a set of integrating and reciprocal interactions between the 
endocrine and nervous system that is controlled by the circadian rhythm and stressful 
events (8, 9). Stress from diverse sources including deranged metabolism, inflammation 
or physical or emotional stressors stimulates the HPA-axis towards increased 
production of GCs. Upon exposure to stressful stimuli, the hypothalamus increases its 
secretion of the hormones vasopressin and corticotropin-releasing hormone (CRH), 
which trigger the pituitary gland to release adrenocorticotropic hormone (ACTH) 
thereby initiating the HPA-axis. ACTH is carried in the blood to the zona faciculata of 
the adrenal cortex, which in response to stimulation by ACTH produces GCs through 
the enzymatic processing of cholesterol, the precursor molecule of steroids, by the 
cytochrome P450 family of steroid hydroxylases and 3-β-hydroxysteroid 
dehydrogenase (3-β-HSD). The principal role of GCs secreted from the adrenals during 
the HPA-initiated stress response is to limit the effectors of the stress response and 
restore homeostasis. For instance, in the fasted state, GCs activates several processes to 
increase blood levels of glucose. These include increasing the stimulation of 
gluconeogenesis in the liver, lowering insulin release from pancreatic β-cells, and 
preventing glucose uptake in peripheral muscle and adipose tissue (7, 9, 10). At the 
molecular level, GCs stimulate hepatic gluconeogenesis by increasing the rate of 
transcription of genes that encode key gluconeogenic enzymes such as 
phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase) 
(7). Thus, the elevation of blood glucose follows the surge of GC secretion. 
Importantly, these metabolic functions of GCs are believed to form the basis for the 
adverse metabolic effects that is accompanied with long-term GC treatment e.g. 
steroid-induced diabetes. 
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Another central function of GCs is balancing the immune response to infection and to 
prevent excessive inflammatory conditions caused by overreaction of the immune 
system. Circulating messengers of inflammation, including the cytokines tumor 
necrosis factor (TNF)α, interleukin (IL)-1 and IL-6 stimulate the HPA-axis during 
inflammation to facilitate increased blood levels of GCs (11, 12). Elevated GCs in turn, 
suppress the activity of cells in the innate and adaptive immune system and modulate 
anti-inflammatory responses (13). Importantly, GCs decrease the global production of 
numerous mediators of inflammation, including pro-inflammatory cytokines, 
prostaglandins, and reactive oxygen and nitrogen species. They reduce leukocyte 
migration to sites of inflammation by inhibiting the expression of adhesion molecules, 
and promote apoptosis of leukocytes, thereby limiting the magnitude of the 
inflammatory response (14, 15). At the molecular level, a pivotal mechanism for the 
immunosuppressive and anti-inflammatory effects by GCs is through inhibition of NF-
κB (Nuclear Factor kappa B), a key regulator of inflammation and a transcription factor 
critically involved in the synthesis of pro-inflammatory mediators, including cytokines 
(IL-1β, TNFα, IL-4, IL-5), chemokines (IL-8, RANTES, eotaxin), enzymes (inducible 
nitric oxide synthase, iNOS; cyclooxygenase-2, COX-2) and adhesion molecules 
(Intercellular Adhesion Molecule-1,  ICAM-1; Vascular Cell Adhesion Molecule-1, 
VCAM-1) (16-19). Global inhibition of this transcription factor and its target genes by 
GCs, therefore, blunts the capacity of the immune system to mount an inflammatory 
response. In addition, GCs concomitantly stimulate the expression of multiple 
important anti-inflammatory genes including IκBα (inhibitor kappa B-alpha), Annexin-
1, GILZ (Glucocorticoid-induced leucine zipper), MKP-1 (MAPK phosphatase-1) and 
IL-10 contributing to a multifaceted suppression of inflammation by GCs (20). Because 
of their potent inhibitory effect on inflammation, exogenous GCs are among the most 
important drugs used today to treat various inflammatory and autoimmune disorders. 
Importantly, GCs prevent their excessive production and HPA hyperactivity by acting 
back on the hypothalamus and pituitary in a negative feed back cycle, which results in 
the decline of elevated GC concentration back to basal levels (7, 8). Patients with 
Cushing’s syndrome have sustained and pronounced blood levels of GCs due to 
pituitary or adrenal tumors that continuously produce ACTH or GCs. Similarly, 
administration of exogenous GCs may lead to Cushing’s syndrome overrunning the 
normal feed-back regulation and giving rise to adverse effects including hypertension, 
hyperglycemia, obesity, muscle and bone catabolism, and impaired wound healing (7, 
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21) and could be considered to be normal but undesirable physiological effects of 
endogenous GCs.  
The majority of GCs in the blood is bound to corticosteroid-binding globulin (CBG) 
and serum albumin and since the biologically active GCs are the unbound or free 
fractions, CBG binding regulates the availability of GCs to target tissues (22). For 
instance, during inflammation the CBG level decreases and as a consequence, the free 
fraction of hormone increases, which in turn suppresses inflammatory responses (23). 
GC availability is also regulated at the tissue level by the 11-β hydroxysteroid 
dehydrogenase (11-β HSD) system, which consists of the two enzymes 11-β HSD1 and 
11-β HSD2. 11-β HSD1 increases the concentration of active GCs by converting 
biologically inert cortisone to biologically active cortisol, whereas 11-β HSD2 converts 
cortisol to cortisone and thereby decreases intracellular concentrations of biologically 
active GCs (24, 25).  
Moreover, there is increasing evidence for extra-adrenal synthesis of GCs in a variety 
of tissues, including the thymus, intestine, skin and brain (26, 27). Whereas adrenal GC 
secretion has coordinated effects on multiple organ system, the local extra-adrenal 
synthesis of GCs results in tissue confined effects of GC action. For instance, in thymus 
there is a a role for endogenous thymic-derived GCs in regulating the homeostasis of 
thymocytes (28). Also, GC synthesis in intestinal epithelial cells was induced after 
immune cell activation, which in turn had an immunoregulatory effect on the activation 
of local T cells (29). 
 
2.1.2 Glucorticoid receptor mechanisms of action 
The GC receptor (GR) is the intracellular receptor to which GCs bind and elicit their 
effects and, as the other members of the nuclear receptor (NR) superfamily, the GR 
functions as a ligand-activated transcription factor. In the absence of GCs, GR resides 
predominantly in the cytosol where it is held in an optimal high affinity configuration 
for its steroid ligands by large multi-protein complexes consisting of several chaperone 
proteins such as heat shock proteins 70 and 90 (Hsp70/90) and co-chaperones such as 
immunophilins FK506 binding proteins (FKBPs) (30). Upon ligand binding, the GR 
becomes activated and hyperphosphorylated and initiates substitution of one 
immunophilin (FKBP51) for another (FKBP52) and recruitment of the transport protein 
dynein (31, 32). The conformational changes of GR lead to the exposure of its nuclear 
localization signals (NLSs), followed by subsequent translocation of GR in complex 
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with hsp90, FKBP52 and dynein into the nucleus where the complex is dissociated and 
GC-activated GR affects target gene expression (Fig. 1).  
Three mechanisms of GC action are known: 1) Transcriptional activation or repression 
of target genes that requires a direct DNA-binding by GR, 2) transcriptional activation 
or repression of target genes that is independent of DNA-binding by GR and 3) 
transcription-independent non-genomic effects (33, 34). Transcriptional activation 
involving GR binding to the DNA occurs when translocated GR homodimerizes and 
binds to specific enhancer elements in regulatory regions of target genes called GC 
response elements (GREs), which can either be “simple” (or primary) GREs, where GR 
binds as the sole component of a regulatory complex or “composite” GREs, where GR 
interacts with at least one additional DNA-bound factor to synergistically mediate 
transcriptional activation (35, 36). The binding of GR to GREs is accompanied by a 
recruitment of transcriptional co-regulators including the p160 co-activator family 
members steroid receptor coactivator 1 (SRC-1), GRIP1 (SRC2/TIF2), and SRC-3 (37-
39). The p160 members interact directly with liganded GR (and other NRs) through 
specific LXXLL motifs (L, Leucine; X, any amino acid) in their nuclear receptor 
interaction domain (NID) and recruit additional co-activators of transcription to the 
complex including histone acetylases p300 or its close homolog cAMP response 
element-binding protein (CREB)-binding protein (CBP). This generates a regulatory 
complex that stabilizes and initiates the basal transcription machinery to facilitate 
transcription, and ultimately, mediates the response of a target gene to GCs.  Contrary 
to the positive GREs, which act as enhancers of transcription, negative GREs (nGREs) 
are suppressors of gene regulation and mediate DNA-dependent transrepression by GR. 
Agonist-bound GR interacts with GREs and can suppress the production mRNA by 
preventing activating transcription factors from accessing their binding sites via 
competition for DNA binding (40, 41). Additionally, GR has also recently been shown 
to associate with either transcriptional co-repressor proteins SMRT/N-CoR (Silencing 
mediator for retinoid or thyroid-hormone receptors/ nuclear receptor corepressor) or 
histone-deacetylase (HDAC)-6 at nGREs to mediate transrepression (42, 43). The 
presence of nGRE in GC-regulated genes has previously been rarely described but a 
recent study suggests that as many as thousand mouse/human ortholog genes contain 
transrepression-mediating nGREs (42). For instance, some nGREs has been found in 
genes involved in feedback mechanisms of GC activity (e.g. Pro-opiomelanocortin, 
POMC; CRH, GR, ACTH/MC2- receptor and 11-β HSD2) and others in genes involved 
in glucose regulation (insulin precursor gene and insulin receptor gene) (42, 43). 
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Additionally, an interesting idea is the possible existence of so called “nonproductive” 
GR binding sites to which the GR interacts but has no apparent effects on 
transcriptional regulation (35, 44, 45). The genomic presence of such binding sites or of 
“occasionally” productive sites, dependent on the cell context, raises the questions of 
when or if GR binding to DNA is translated to an effect on transcription. 
 
 
 
Figure 1. GCs act via the intracellular GR, which can regulate gene expression by binding to 
GREs in the DNA or independently of GRE-binding through protein-protein “tethering” 
interactions with promoter-bound TFs. TF = Transcription factor, TFBS = TF binding sites, HSP 
= Heat-shock protein 
GR also regulate transcription through DNA-independent mechanism, where it does 
not itself bind specifically to DNA, but is recruited through interaction with another 
DNA-bound factor. This mechanism of transcriptional regulation is often referred to as 
“tethering” and can either enhance or suppress gene transcription depending on the 
activating and promoter-bound transcription factor with which GR interacts and gene 
context (46)(Fig. 1). For instance, GR interacts with signal transduction and activator of 
transcription 5 (Stat5) independently of its DNA binding function to stimulate 
expression of the β-casein gene (47), whereas the anti-inflammatory gene product IL-
10 was recently shown to be activated by GCs through GRE-independent mechanisms 
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involving Stat3 (48). Additionally, the GR induces expression of the anti-inflammatory 
protein MKP-1 through a tethering mechanism involving the promoter-bound 
transcription factor C/EBP (CCAAT Enhancer binding protein) (Paper I). 
Interestingly, other studies have demonstrated a cooperative ability of GR and C/EBP 
for transactivation (49), but GR has also been shown to inhibit transcription driven by 
C/EBP of certain genes by recruiting SMRT (50). This highlights a level of complexity 
of the transcriptional regulation by GCs that is above the mere identity of transcription 
factors interacting with GR at target genes.  
In addition to positive tethering, agonist-bound GR transcriptionally inhibits genes 
involved inflammation and proliferation through negative tethering interactions with 
transcription factors pivotal for these processes such as NF-κB and Activator Protein 
(AP)-1 (51). To date, several mechanisms for transcriptional repression by GR of NF-
κB have been proposed, many of which describe a direct protein-protein interaction by 
GR with the NF-κB subunit p65 (Fig. 2) (52). Early observations suggested that GR 
was able to represses NF-κBs (p65, p50 and c-Rel) by affecting their ability to bind to 
the DNA (53). More recent studies however, indicate that GR mainly interacts with 
NF-κB at a variety of inflammatory genes and imposes transrepression without 
affecting the ability of NF-κB to access the DNA. For instance, GR may repress a 
subset of NF-κB target genes that require the physical interaction between promoter-
bound NF-κB and co-activator IRF3 (Interferon regulatory factor 3) for transactivation 
by binding to p65 and thus blocking the formation of p65-IRF3 complexes (54). 
Conversely, when signals induce p65 to act as the critical co-activator of promoter-
bound IRF3, GR binding to p65 prevents recruitment of p65 to IRF3 target genes and 
thus terminates the NF-κB response of these genes (54). Furthermore, GR has been 
suggested to sequester GRIP1 from IRF3 and use it as a co-repressor in GC-mediated 
inhibition of NF-κB (14). The GR/GRIP1 recruitment to the p65 DNA complex was 
recently demonstrated for the GC repression of bacterial lipopolysaccharide (LPS)-
dependent induction of the COX-2 (55). Moreover, GR have been reported to act as a 
repressor of NF-κB transactivation by manipulating the basal transcription machinery at 
inflammatory promoters. For instance, GR has been shown to inhibit NF-κB 
transcription of IL-8 by by blocking p65 recruitment of P-TEFb (Positive Transcription 
Elongation Factor b) and consequently impairing the phosphorylation of the serine 2 
residue of the RNA polymerase II necessary to initiate transcription (56). Also, GR 
associates with HDAC2 in vivo and represses p65 histone acetylase (HAT) activity (57) 
demonstrating that GCs can inhibit NF-κB access to its DNA binding sites through GR-
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mediated deacetylation of histones. In addition, competition for limited amounts of co-
regulators necessary that are shared by NF-κB and GRs to regulate transcription, 
including CREB and CBP, have been suggested to lead to a decreased gene 
transcription of inflammatory gene products (58-60), but remain controversial as a valid 
mechanism for NF-κB repression by the GR (61-63). Furthermore, GR may also inhibit 
the activity of NF-κB signaling by interacting with MSK-1 (mitogen- and stress-
activated protein kinase-1), a potentiating kinase for NF-κB activity, and block its 
ability to phosphorylate NF-κB at serine residue 276 (64). Conversely, NF-κB has been 
shown to mutually inhibit transactivation of promoter-bound GR by p65 tethering to 
the GR-bound co-activator nTrip6 (nuclear isoform of Thyroid receptor-interacting 
protein 6) (65, 66). Interestingly, GR and NF-κB have under some conditions also been 
shown to cooperatively transactivate genes, e.g. Toll-like receptor 2 (TLR2) (67). Thus, 
a large body of literature highlights an intricacy in the cross-talk mechanisms between 
GR and NF-κB ranging from mutual antagonism through various transrepression 
mechanisms to cooperation that is dependent on gene and cell context. 
Lastly, GCs also exert their effects via rapid nongenomic mechanisms that are 
independent of GC-regulation of gene transcription. These nongenomic actions of GCs 
may occur without receptor involvement, via cytosolic GR, or through interactions with 
membrane-bound GRs  (50, 68, 69). In some cases, GC action at the post-
transcriptional level also appears to be independent from de novo gene expression, such 
as GC-mediated acceleration of macrophage chemotactic protein -1 (MCP-1) mRNA 
degradation (70). Interestingly, the cytoplasmic GR has recently been demonstrated to 
function as a RNA-binding protein that promotes mRNA degradation (71). In addition, 
GCs have been shown to rapidly inhibit the release of the inflammatory molecule 
prostaglandin E2 (PGE2) regardless of the presence or absence of protein synthesis 
inhibitors, indicating this to be a transcription-independent nongenomic mechanism by 
GCs (72).  
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Figure 2. A selection of mechanisms proposed for GR inhibition of NF-κB activity. A. Blocking 
recruitment of co-regulators by NF-κB. B. Blocking the recruitment of NF-κB to promoter-bound 
IRF3. C. Recruitment of HDACs by GR to NF-κB controlled genes. D. Blocking phosphorylation of 
NF-κB by interfering with NF-κB kinases e.g. MSK-1. E. GR transactivation of inhibitory gene 
products that block NF-κB activity 
 
2.1.3 Transcriptional regulation by the GR and its relevance for the 
anti-inflammatory effects of GCs 
The significance of the various transcriptional regulatory capabilities by GR with 
regards to the anti-inflammatory effects of GCs is under debate. The fact that numerous 
anti-inflammatory actions by GCs such as cytokine gene repression and immune cell 
proliferation have been shown to involve the transrepression capability of GR whereas 
the clinically undesired effects induced by GCs, such as increased glucose production 
in the liver, predominantly involve transactivation has provided a rationale tilted 
towards dissociating these two functions completely from each other in order to achieve 
selective effects with GC therapy (5, 73). Considerable support for this hypothesis 
came from in vivo experiments in mice in which the wild-type GR had been replaced 
by the dimerization-deficient mutant (GRdim) (74). Mutations in the dimerization 
interface of GR had previously been shown to cause a loss of ability by GR to 
transactivate via GREs while sparing the capability of GR to transrepress (75-77). 
Indeed, in these mice induced pro-inflammatory gene expression was still inhibited by 
GC treatment (75, 78). Importantly, while GC-inhibition of inflammatory processes 
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(e.g. 12-O-tetradecanoylphorbol-13-acetate (TPA) -induced skin inflammation or LPS-
induced endotoxemia) where comparable between wild-type and mutant mice, the 
GRdim mutant poorly induced expression of model genes considered as representative 
of GC-induced side effects, including the gluconeogenic enzymes TAT (Tyrosine 
aminotransferase) and PEPCK. 
From this premise, “dissociated” GC ligands (termed e.g. selective GR agonists; 
SEGRAs, or selective GR modulators; SGRMs), capable of favoring transrepression 
over transactivation, have been developed to provide the breakthrough gateway to safer 
GCs that preserve their anti-inflammatory properties but have fewer side effects (79-
81). Although these compounds demonstrate dissociation in vitro using reporter gene 
assays (e.g. GRE-luc and NF-κB-luc) and at some biomarker genes (e.g. IL-6 and 
PEPCK) the results in vivo are less clear-cut. While some dissociated compounds have 
been shown to inhibit the progression of certain inflammatory models to a reasonable 
extent as compared with “classic” GCs (82-84), a reoccurring problem for many 
selective GCs in vivo, ultimately, includes either a poor anti-inflammatory efficacy or a 
limited loss of adverse effects (85-89). Similarly, GRdim mice have in later studies been 
shown to be GC-insensitive in experimental models of contact allergy (89) and arthritis 
(90) and are not protected from GC-induced muscle athropy (91) or osteoporosis (92). 
The reduced therapeutic efficacy of dissociated compounds could be because 
transactivation, which is the function that is purposely avoided with the use of these 
dissociated GC agonist, is required for the full anti-inflammatory effects of GCs. 
Indeed, GCs stimulate the expression of multiple genes with distinct anti-inflammatory 
properties (20, 93). For instance, in addition to transrepression of NF-κB through 
protein-protein interaction between GR and p65, induction of IκBα by GCs has been 
implicated as relevant for NF-κB repression by GCs (94-96). Moreover, GCs induce 
expression of GILZ and MKP-1 in order to block inflammatory gene transcription. 
Whereas MKP-1 targets and inhibits pro-inflammatory MAPK signaling pahways (97), 
GILZ have been shown to interact directly with AP-1 and NF-κB and impair their 
functions (98). Furthermore, GCs stimulate the expression of IL-10 and Annexin A1, 
the former a potent anti-inflammatory cytokine and the latter a calcium-dependent 
phospholipid binding protein that inhibits production of pro-inflammatory mediators 
such as prostaglandins and leukotreines (99, 100). Interestingly, Annexin A1, induced 
by GCs, was recently discovered to directly interact with the NF-κB p65 subunit and 
suppress its transcriptional activity by preventing NF-κB binding to DNA (101). 
Indeed, several recent studies have implicated both GR homodimerization and 
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transactivation, along with transrepression, as relevant for the complete anti-
inflammatory effects of GCs (89, 102). Furthermore, GR mutants, including GRdim, 
along with a selection of dissociated GC compounds have been shown to still be 
capable of stimulating the expression of genes such as IL-10, MKP-1 and 
phenylethanolamine N-methyltrasferase (PNMT), which all have been shown to 
contain atypical binding sites for GR (86, 97, 103-105), thereby demonstrating that the 
GRdim mouse strain does not display a complete separation of transactivation and 
transrepression. Thus, both anti-inflammatory and adverse effects still observed with 
some dissociated GCs and in GRdim mice might be due to a residual transactivation 
capability by GCs of target genes regulated through GRE-independent mechanisms. In 
particular, MKP-1 may embody both wanted and unwanted effects of GCs. On one 
hand, MKP-1 has been implicated as a potent agent for the anti-inflammatory actions of 
GCs (see MAPK section). On the other hand, MKP-1 has also been shown to mediate 
GC-inhibition of osteoblast proliferation (106, 107), which could relate it to GC-
induced osteoporosis. When forcefully expressed, MKP-1 induces muscle atrophy 
(108), which is also a side effect observed with prolonged and high-dose use of GCs. 
Importantly, like the anti-inflammatory action of GCs, side effects of GC therapy could 
also involve both transactivation and transrepression capabilities of GR. For instance, 
both GC-inhibition of cytokines, including IL-11, via transrepression by monomeric 
GR of AP-1 (92) as well as transactivation of e.g. the Wnt signaling antagonist DKK-1 
(Dickkopf-1) (109) (see Wnt section) by GCs have been shown to inhibit proliferation 
and differentiation of osteoblasts and have both been suggested to be underlying 
mechanisms for GC-induced osteoporosis. In addition to GRE –mediated transactivaton 
of hepatic PEPCK and TAT by GCs (7), transrepression of the insulin precursor gene in 
pancreas and the insulin receptor gene in the liver via their recently discovered nGREs 
might concomitantly contribute to insulin resistance and the development of steroid 
induced diabetes (42). Thus, the uncoupling of wanted GC effects from unwanted 
effects through separation of transactivation and transrepression functions of GR may 
be difficult to achieve since an effect may involve both these functions to various extent 
(Fig. 3).  
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Figure 3. Models proposed for GC-effects. A. A model suggesting dissociated GR functions for separate GC 
effects. B. A model suggesting a contribution of both transactivation and transrepression functions of GR for 
anti-inflammatory effects by GCs. C. A model highlighting an involvement of both GR functions for adverse 
effects by GCs  
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2.1.4 Glucocortiocid receptor structure and function 
The GR belongs to the superfamily of of ligand-regulated nuclear receptors and is 
produced from a single GR gene located on chromosome 5 (5q31-32), which consists 
of 9 exons. Alternative splicing events can give rise to GR isoforms that differ at the C-
terminus (GRβ) or within the central structure of GR (GRγ) (110). Furthermore, 
alternative translation initiation generates isoforms that lack parts or all of AF-1 (111). 
The full length GRα isoform (777 amino acids in human) is widely expressed and is 
responsible for GC transactivation and transrepression (throughout this work referred to 
as GR) whereas the relative expression of the other GR isoforms can modulate GC 
sensitivity in a cell-specific manner. For instance, GRβ is a GC-independent negative 
regulator of GR that targets GR for heterodimerization and has been implicated in GC-
resistance (112). Like other members of the NR family, GR is a modular protein that 
contains three major domains including the N-terminal domain (NTD), the central 
DNA-binding domain (DBD), and the C-terminal ligand-binding domain (LBD) (Fig. 
4) (46). A flexible region of the molecule, termed the hinge region, separates the DBD 
and LBD. Two nuclear localization signals, NL1 and NL2, are located at the 
DBD/hinge region junction and within the LBD, respectively. 
 The GR DBD is a highly evolutionary conserved region and contains two zinc finger 
motifs crucial for the DNA binding of GR to GREs in GC-target genes. These similar 
zinc finger structures, each with a Zn ion held in center by four cystein residues have 
been shown to have separate functions. The N-terminal zinc-finger contains three 
amino acids that form the P-box, which allows GR to interact with GREs in the DNA 
of target genes. The C-terminal zinc finger contains the D-box, which plays an 
important role in homodimerization of GR and together the two zinc finger structures 
promote transactivation by facilitating coordinated binding of both DBD motifs of 
homodimerized GRs to palindromic GREs in GC responsive target genes. Interestingly, 
recent studies have shown that the GRE itself, depending on its sequence composition, 
may influence the three-dimensional structure of the DBD resulting in the expression of 
certain GC genes by liganded GR to be allosterically fine-tuned and this could in part 
explain the gene-specific transcriptional effects of GR (113).  
 The NTD contains a strong ligand-independent transcriptional activation function 
(AF1) that binds various co-regulators, including chromatin remodeling factors (e.g. 
Brahma-related gene-1 (BRG1), histone modifiers (e.g. HDAC-6, CREB and 
p300/CBP-associated factor (P/CAF)), and components of the basal transcription 
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machinery proteins of the transcription intitiation complex, such as RNA polymerase II, 
TATA-binding protein (TBP) and TBP-associated factors (TAFs) (114). Furthermore, 
the NTD bears the most amino acid residues of GR prone to post-translational 
modifications, which allows other signaling pathways to influence GC signaling at the 
post-translational level (115). The human GR has phosphorylation sites at serines 113, 
141, 203, 211, 226 and 404 and the status of GR phosphorylation at these sites alters its 
transcriptional activity. Phosphorylation of residues S203 and S211 by kinases such 
cyclin-dependent kinase (CDK) 2 and CDK5 has been shown to increase GR 
transactivation (115). In contrast, phosphorylation of GR at S404 by Glycogen synthase 
kinase 3 β (GSK3β) enhances nuclear export of GR and diminishes its ability to 
regulate transcription. Other post-translational modifications of the GR NTD that alter 
the function of GR have been confirmed by the use of GR mutants and include 
SUMOlaytion (modification by Small Ubiquitin-like Modifier) at lysine 293, 277 and 
703, ubiquitination at lysine 419 and acetylation at lysine 480, 492, 494 and 495 (115). 
Moreover, since alternative translation initiation of the GR mRNA generates naturally 
occurring isoforms of GR that have varying lengths of the NTD, this may contribute to 
the pleiotropic effects of GR such as the ability to interact with other proteins and 
regulate transcription (116).  
The LBD, contains 12 α-helices and four β-sheets that form a hydrophobic pocket that 
binds GCs (117). A second activation function (AF2) that interacts with coregulators in 
a ligand-dependent manner is embedded in the LBD. The AF-2 region, like the AF-1 
region in NTD, interacts with histone modifiers p300/CBP, p300/CBP-associated factor 
(p/CAF) and members of the p160 family of co-activators (e.g. SRC1, GRIP1) on GC 
target genes to drive transactivation (114). Many of these co-activators contain several 
specific LXXLL sequence motifs that interact with helix 12 in the AF-2 region of the 
LBD in response to GC ligand binding. Importantly, different GC agonists may 
influence co-regulator interaction with the AF-2 region. Dexamethasone, a potent GC 
agonist, strongly promotes binding of GR to the TIF2 co-activator protein, which 
mediates the activating functions of GR by acetylating histones making the target gene 
DNA more accessible for transcription (117). Dexamethasone has also been shown to 
prevent GR recruitment of nuclear receptor co-repressor N-CoR, whereas RU-486, a 
GC antagonist, increases GR interaction with co-repressors N-CoR and SMRT (118). 
Furthermore, several dissociated GC ligands have demonstrated capabilities to alter GR 
interaction with its co-regulators. GR when bound to AL-438, a non-steroidal 
alternative to classical GCs, is incapable to interact with co-activator PGC-1, a GR co-
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activator important for hepatic gluconeogenesis, while it remains fully capable of 
binding to TIF-2 (119). Since the LBD contributes to GR dimerization, some of these 
dissociated GCs are also aimed to prevent the required GR dimer formation for 
transcriptional activation from GREs in target genes. Compound A (Cpd A), a non-
steroidal plant-dervied phenyl phenyl aziridine precursor that has been shown to induce 
GR monomer formation, does not enhance expression of genes including Glucose-6-
phosphatase, PEPCK, GILZ but maintains its transrepression capabilities such as the 
down-regulation of TNFα-induced and NF-κB driven expression of pro-inflammatory 
markers (IL-6 and IL-8) (120).  
 
 
 
 
 
Figure 4. Schematic overview of the GR protein structure. 
 
2.1.5 Glucorticoid receptor mutants 
Since the cloning of full length GR in 1985, the core functions and relevance of the GR 
regions for the GC effects has been determined by subjecting the GR to mutagenesis 
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analysis (Fig. 4). Indeed, several GR mutants (a selection of them described below) 
have been used as investigative tools to explore GR function (121).  
A point mutation, E755A, in the LTD was shown to inhibit the ligand-dependent 
interaction of GR with LXXLL-containing co-activators and led to a decrease in 
transactivation, but had little effect on transrepression (61), implicating these functions 
to be involving separate functions of the GR. Similarly, a specific point mutation, 
A465T, in the second zinc finger of the DBD generates the dimerization deficient 
mutant, GRdim, which, although it is not completely transcriptionally inactive, does not 
bind to or transactivate via GREs on the DNA of GC-sensitive genes (74). However, 
the GRdim is still capable of transrepressing NF-κB and AP-1-mediated gene regulation 
in vitro and in vivo, suggesting that transcriptional repression by GR can occur 
independently of both GRE-binding and dimerization. Whereas mutations in the 
dimerization box in the DBD or in regions necessary for full transcriptional GR activity 
do not affect GC repression of p65-dependent transcription, mutations of arginine or 
lysine (Arg-488 or Lys-490 in the rat GR) in the second zinc finger abolished the 
ability of GR to inhibit p65 activity (76). Deletions in the second zinc finger result in a 
loss of GC-mediated repression of IL-6 (122), which further illustrates the importance 
of the DBD for the transrepression mechanism. Other GR DBD mutants, such as 
GRLS7, which carries a double point mutation (P493R/A494S, rat nomenclature), does 
not transactivate through GREs but inhibits the transcriptional activity of NF-κB and 
AP-1 (76, 123) while a similar rat GR DBD mutant, GRR488Q, is able to transrepress 
AP-1 but not NF-κB regulated transcription activated by TPA (123). Interestingly in 
paper II, we show that the GRR488Q is capable of inhibiting NF-κB activated by TNFα, 
but no activated by TPA, implicating that repression of NF-κB by GR, through the 
DBD, may depend highly on the signaling pathway that is employed to activate NF-κB.  
Although GR DBD mutants have been shown to be deficient in their capability to 
homodimerize and transactivate via GREs, some of them are still capable of 
transactivating genes that do not require GREs for their activation by GCs. For 
instance, the GRdim mutant has in studies been shown to induce gene expression of the 
anti-inflammatory protein MKP-1 (97), suggesting that both transrepression and 
transactivation can occur independently of homodimerization and DNA-binding by 
GR.  
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2.2 NF-κB 
The NF-κB family of inducible transcription factors is the target of multiple pro-
inflammatory and extracellular stimuli, such as stress, cytokines, UV radiation, 
bacterial and viral antigens, and is a key participant in various biological processes, 
including proliferation, development and most notably regulation of innate and 
adaptive immunity and inflammatory response (17). There are five family members of 
NF-κB, named NF-κB1 (p50 and its precursor p105), NF-κB2 (p52 and its precursor 
p100), p65 (or RelA), c-Rel and RelB, which all carry the highly conserved 300 amino 
acid long signature motif, N-terminal Rel homology domain (RHD). This domain is 
responsible for homo- and heterodimerization of the NF-κB subunits and sequence-
specific DNA-binding to kB enhancer element in the regulatory regions of NF-κB 
target genes. In addition, p65, c-Rel and RelB contain a C-terminal transcriptional 
activation domain (TAD), whereas p100 and p105 contain C-terminal ankyrin repeats 
that become proteasomally processed to generate p52 and p50, respectively. In their 
mature form, p52 and p50 heterodimerize with TAD-containing NF-κB family 
members and normally, RelB predominantly form heterodimers with p52/p100 and p65 
and c-Rel preferentially binds to p50 (124). 
In resting cells, NF-κB is kept inactive through its association with inhibitory IκB 
proteins in the cytoplasm, which interacts with NF-κB through its ankyrin repeats 
domain and blocks the exposure of the nuclear localization signal (NLS) motifs of NF-
κB. Following cell stimulation, the IκB inhibitory proteins become phosphorylated by 
IκB kinase (IKKs) complexes, which leads to the IκBs becoming polyubiquitinated and 
proteolytically processed. Consequently, the release of NF-κB from IκB unmasks its 
NLS, which results in a nuclear entry of transcriptionally active NF-κB. Inside the 
nucleus NF-κB binds to and stimulates expression of genes involved in immune 
regulation and inflammatory response (124).  
Two distinct NF-κB pathways, the canonical (or classical) and the non-canonical (or 
alternative) NF-κB pathway, have been characterized. Although these two NF-κB 
pathways follow the general pattern of activation outlined above, they are activated by 
distinct stimuli, use different IKK complexes to promote nuclear accumulation of 
separate NF-κB heterodimer complexes that, ultimately, stimulate the expression of 
individual subsets of target genes (124-126).  
In the canonical NF-κB pathway, IκBα holds the p65/p50 heterodimer complex 
inactive in the cytoplasm. When cells are triggered by pro-inflammatory signals, such 
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as cell surface binding of TNF ligands to TNFRs, engagement of TLR signaling and 
ligation of antigen receptors on lymphocytes, an IKK complex comprising of two 
catalytic subunits, IKKα and IKKβ, and a regulatory subunit, NEMO becomes 
activated (124). Through the catalytic activity of IKKβ, the IKK complex 
phosphorylates IκBα on serine residues 32 and 36. This leads to a polyubiquitination of 
IκBα and its degradation by the 26S proteasome and allows nuclear translocation of 
liberated p65/p50. In the nucleus p65/p50 can bind to and transcriptional activate a 
broad range of pro-inflammatory mediators, such as cytokines (TNFα, IL-1β, IL-6, 
GM-CSF), chemokines (CCL2, RANTES, IL-8, CXCL2), growth factors (epidermal 
growth factor, EGF; fibroblast growth factors, FGF), cell surface receptors (TNFR, 
TLR), adhesion molecules (ICAM-1, VCAM-1, E-selectin) and enzymes (iNOS, COX-
2) (127). With the wide battery of pro-inflammatory mediators under its direct control, 
the canonical NF-κB signaling pathway plays an essential role in mounting 
inflammatory responses. Importantly, the canonical NF-κB pathway limits its own 
activity and prevents uncontrolled expansion of inflammation by regulatory feedback 
mechanisms. Crucially, NF-κB up-regulates the expression of IκBα, which binds to the 
active p65/p50 complexes released by previous degradation of IκBα, retains them back 
in the cytoplasm and thereby renders them inactive (124, 125, 128).  
The “alternative” or non-canonical NF-κB pathway is, unlike the canonical NF-κB 
pathway, activated by a narrow subset of predominantly cell developmental stimuli, 
including ligation of the Lymphotoxin β receptor (LTβR) by LTα1β2 and LIGHT, 
stimulation of BAFF (B-cell activating factor) on B cells, RANKL (Receptor activator 
of NF-κB ligand), CD40 and TWEAK (TNF-like weak inducer of apoptosis) (129). 
This pathway, in contrast to the canonical NF-κB pathway, does not involve NEMO 
and IKKβ mediated degradation of IκB, but relies upon homodimers of IKKα for its 
signaling activity (124). Importantly, the activation of IKKα in non-canonical NF-κB 
signaling requires the stabilization and activation of its direct upstream regulator, NIK 
(NF-κB inducing kinase), which is kept at low levels by constitutive proteasomal 
degradation in resting cells. The activation of the non-canonical NF-κB pathway results 
in the inhibition of degradation of NIK allowing the NIK protein to reach the sufficient 
threshold level to activate IKKα by phosphorylation. NIK-activated IKKα targets 
inactive RelB/p100 heterodimers in the cytoplasm and phosphorylates the p100 on 
serine residues 865, 869 and 871, which initiates the process of polyubiquitination and 
proteolytic cleavage of p100 to generate p52. The RelB/p52 complex, consequently, 
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translocates into the nucleus where it activates immune regulatory genes, including 
homeostatic chemokines CXCL12 and13, CCL19 and 21, immune growth factor BAFF 
and anti-apoptotic gene products B-cell lymphoma (BCL)-xl and BCL-2 (125, 130, 
131). Through the up-regulation of these and other organogenic chemokines, growth 
factors and anti-apopoptic regulators, the non-canonical NF-κB pathway controls 
specific immune functions, including lymphoid organogenesis (splenic organization 
and germinal center formation), trafficking of lymphocytes to lymphoid organs, and B-
cell proliferation, maturation and survival (125, 129-132).  
 
2.3 MAPK SIGNALING PATHWAY 
The mitogen-activated protein kinase (MAPK) signaling pathways are evolutionary 
conserved signal transduction pathways that relay information from the extracellular 
environment, into cellular compartments to generate a cellular response. MAPKs 
respond to a wide array of extracellular stimuli (mitogens, stress, cytokines, phorbol 
esters, ultraviolet radiation, and growth factors) and influence many key biological 
processes such as proliferation, development, differentiation, apoptosis, and 
inflammation through the activity of intracellular signaling cascade events (133, 134). 
Importantly, the MAPK pathways can also coordinate and amplify signals from other 
activated signaling pathways to generate various cellular response patterns (115, 134). 
There are at least three known MAPK signaling pathways, including the extracellular 
signal-regulated kinase (ERK) pathway, c-Jun N-terminal kinase (JNK) pathway and 
p38 MAPK pathway and all three members of the MAPK family are serine/threonine 
specific protein kinases that share a hallmark feature in their requirement of a dual 
threonine and tyrosine phosphorylation to display maximal activity. MAPKs become 
activated in a three-step regulatory intracellular phosphorylation “cascade” involving 
MAPK kinase kinase (or MEKK), MAPK kinase (or MEK) and MAPK. This MAPK 
cascade is initiated when a MEKK is activated by extracellular stimuli and 
phosphorylates serine and threonine residues of its substrate MEK, which becomes 
activated. The MEK in turn targets and phosphorylates the threonine and tyrosine 
residues of MAPK. Activated MAPKs relay the signal by phosphorylating other 
downstream kinases or, as in the case of ERK1/2, translocate into the nucleus and 
directly phosphorylate regulators of transcription (e.g. AP-1) and thereby critically 
influencing their transcriptional activity (135, 136).  
The MAPKs respond to many inflammatory signals and mediate inflammatory 
responses by regulating transcription and stabilizing the mRNA of key pro-
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inflammatory mediators, including COX-2, IL-6, IL-1β, TNFα and IL-12 (115, 137-
140). Furthermore, MAPKs can influence other inflammatory pathways including the 
canonical NF-κB pathway. For instance, the p38 MAPK have been shown to mediate 
IκB phosphorylation/degradation and NF-κB activation by various stimuli (141, 142). 
Additionally, the serine residue 276 of p65 has been shown to be a substrate target for 
ERK- and p38-activated MSK-1 and inhibition of activated p38 MAPK and ERK1/2 
results in a decrease of phosphorylation of the p65 NF-κB subunit (143). The 
phosphorylation of the serine residue 276 of p65 by MAPK-activated MSK-1 has been 
demonstrated to be important for the transcriptional regulation of target genes by the 
canonical NF-κB signaling pathway. The p38 MAPK has also been implicated in the 
phosphorylation of the NF-κB co-activator p300, which results in its increased activity 
and association with NF-κB (144). Also, the MEKK TAK1 (Transforming growth 
factor β–activated kinase-1) has been shown to phosphorylate NIK in response to IL-1 
stimulation and, by acting upstream on the NIK-IKK pathway, influence NF-κB 
activity (145).  
Importantly, the limiting of duration and amplitude of MAPK signaling pathways is 
profound for normal cell function and since these pathways are strong conductors of the 
inflammatory response, strict control mechanisms exist to prevent their excessive 
activity. Inactivation of MAPKs occurs through dephosphorylation at their 
phosphothreonine and phosphotyrosine residues by specific dual-specificity (Thr/Thy) 
MAPK phosphatases (MKPs) (146). The archetypical member of the MKP family is 
MKP-1 (or DUSP1), which has been shown to interact with and dephosphorylate active 
ERK1/2, JNK1/2 and p38MAPK and thus regulate the activity of MAPK-dependent 
effects on gene transcription (147). MKP-1 expression is induced by pro-inflammatory 
stimuli through MAPK signaling pathways and plays an important role in the negative 
feedback inhibition of various cellular responses mediated by p38 MAPK, JNK and in 
some cells ERK1/2 (148, 149). The up-regulation of MKP-1 has been suggested to 
contribute to the destabilization of pro-inflammatory mRNAs (150) and to inhibit 
transcription factors that regulate the expression of these messengers (149, 151). MKP-
1−/− mice have been shown to have elevated MAPK signaling activities and be 
hypersensitive to inflammatory insults, such as LPS, where an already low dose 
challenge with LPS results in significantly increased amounts of serum cytokines, 
severe hypotension, multi-organ failure and increased mortality due to sepsis (152). 
Furthermore, absence of MKP-1 increases systemic levels of pro-inflammatory 
cytokines and exacerbates disease development in a mouse model of rheumatoid 
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arthritis (153). Thus, MKP-1 appears to be an important negative regulator of 
inflammatory responses, and its induction has a critical role for the restraint of pro-
inflammatory cytokine production by stimulated MAPKs. Additionally, MKP-1 
expression is stimulated by GCs and provides GCs with a capability of regulating 
MAPK signaling (154, 155). Since MAPKs regulate inflammatory responses, the 
inhibition of these signaling molecules through the increased expression of MKP-1 by 
GCs has been studied for the ability of GCs to exert their anti-inflammatory effects. For 
instance, GCs was shown to inhibit LPS-induced JNK and p38 MAPK in MKP-1+/+ but 
in not MKP-1-/- bone marrow derived macrophages (97). In the MKP-1 knock out cells 
inhibitory effects of GCs on distinct inflammatory genes where shown to be either 
strongly MKP-1 dependent (e.g. IL-1α), independent of MKP-1 (e.g. colony 
stimulating factor 2 or CSF2), or partially dependent on MKP-1 (e.g. TNFα, COX-2, 
and others), which demonstrated a partial and gene-specific dependency of MKP-1 up-
regulation by GCs for their inhibitory activity. In addition to macrophages, GC-
induction of MKP-1 has also been implicated in the inhibition of pro-inflammatory 
gene expression by GCs in microglia (156), vascular endothelial cells (157) and airway 
smooth muscle cells (158). In vivo, MKP-1−/− mice show enhanced mast cell 
degranulation and are highly susceptible to anaphylaxis, but were still shown to be 
sensitive to GCs (159). This suggested that some anti-inflammatory effects of GCs in 
vivo were independent of MKP-1, although they could involve GC-induction of other 
MAPK-phosphatases (159). In contrast, another in vivo study observed that GC-
treatment completely protected wild-type MKP+/+ mice from mortality caused by a high 
dose of LPS, whereas it only offered a partial protection in MKP-1-/- mice (160). These 
studies indicate that the anti-inflammatory effects of GCs can be partially dependent on 
GC-induction of MKP-1 expression and inactivation of MAPKs both ex vivo and in 
vivo. Furthermore, since MAPK-signaling has been demonstrated to influence 
transcriptional activity of NF-κB, MKP-1 induction by GCs might constitute an 
additional mechanism by which GCs may repress NF-κB activity. In endothelial cells, 
GC-induction of MKP-1 inactivated TNFα-activated p38 MAPK and inhibited 
expression of E-selectin, a gene that is largely regulated by NF-κB, whereas in 
endothelial MKP-/- cells, GCs did not inhibit the TNFα-activated E-selectin expression 
(157). Moreover, in human bronchial epithelial cells where MKP-1 was down-
regulated using RNA interference, GC-inhibition of p38 MAPK-activated NF-κB was 
partially reversed (151). Furthermore, the p65 kinase MSK-1 is not turned off in the 
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absence of MKP-1, allowing pro-inflammatory pathways to continue in an uncontrolled 
manner (161). Thus, GC-induction of MKP-1 could provide an additional mechanism 
for MSK-1 and NF-κB control by GCs. However, the relevance for GC-up-regulation 
of MKP-1 for its ability to inhibit NF-κB may be cell dependent. For instance, we 
demonstrate in paper II that inhibition of TNFα or TPA-induced NF-κB activity in 
human embryonic kidney cells does not require MKP-1 up-regulation by GCs. 
Similarly, GCs were shown to inhibit TLR4-dependent COX-2 gene induction in 
macrophages via a combinatorial mechanism that involves both MKP-1-mediated 
inhibition of AP-1 and GR-GRIP1-mediated transrepression of p65 (55). Taken 
together, the relevance of the ability by GCs to induce MKP-1 expression for their 
capacity to inhibit NF-κB still remains somewhat contradictory and could depend on 
cell and gene context.  
Moreover, MAPKs can reciprocally inhibit both GR and MPK-1 and thus protract their 
own signaling activity. For instance, JNK phosphorylates rat GR at position S246 
(S226 conserved in human) and inhibits transcriptional activation by GR (162). In 
addition, cooperation of ERK and the E3 ubiquitin ligase SCFskp2 can initiate 
proteolysis of MKP-1 and thereby sustain MAPK ERK signaling (163). These mutually 
antagonistic cross-talk mechanisms, involving altered phosphorylation status of GR, 
decreased expression of MKP-1 and persistent activity of MAPKs, have been proposed 
to contribute to GC-insensitivity (164, 165). 
 
2.4 WNT SIGNALING PATHWAY 
Wnts constitute a large family of secreted glycoprotein ligands that are essential for a 
wide array of developmental and physiological processes, including proliferation, 
differentiation, apoptosis and survival, by activating multiple intracellular signaling 
cascades (166). Wnt signaling has been implicated in maintaining neuronal and 
hematopoietic stem cells in a self-renewing state and is central to bone development 
and homeostasis (167, 168). Wnt signals are transduced in at least two distinct ways, a 
well-established canonical Wnt pathway, which is dependent on the β-catenin, and a 
noncanonical pathway or pathways that are β-catenin independent. In the absence of 
Wnt proteins, β-catenin is constitutively degraded in the cytoplasm of cells by the β-
catenin destruction complex, which consists of GSK3β, Axin, APC (adenomatous 
polyposis coli), and CKIa (casein kinase Ia). The continous degradation of synthesized 
β-catenin is achieved by phosphorylation of β-catenin by CKIa and GSK3B, which 
results in polyubiquitination of β-catenin by β-transducin and ubiquitinated β-catenins 
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are consequently degraded by proteasomes. Activation of canonical Wnt signaling 
occurs when a Wnt ligand binds to its receptor, the Frizzled (FZD) family of proteins, 
and then along with FZD binds to lipoprotein-related receptor (LRP)5 or LRP6. The 
Wnt-FZD-LRP5/6 complex activates Dishevelled (Dvl), which destabilizes and 
disrupts the destruction complex of β-catenin by removing Axin away from the 
complex. This blocks the degradation fate of cytosolic β-catenin, which translocates to 
the nucleus where it associates with transcription factors from the lymphoid enhancer 
factor (LEF)/T-cell factor (Tcf) family and enhance target gene transcription of genes 
associated with enhanced cell growth (e.g. cyclin D1, c-Myc, C-jun and VEGF) (169, 
170). The non-canonical Wnt pathway uses common intracellular components as the 
canonical Wnt pathway to relay its signals, including Dvl, axin, and GSK3β, but is β-
catenin-independent. This pathway has been shown to be involved in the regulation of 
intracellular calcium. Binding of noncanonical Wnt ligands such as Wnt5a causes a 
calcium flux that leads to the activation of Ca2+-dependent effectors such as 
calcium/calmodulin dependent kinase II (CamKII), nuclear factor associated with T 
cells (NFAT), and proteins kinase C (PKC), which regulate a diverse battery of genes 
(171-173). Importantly, CAMKII activates TAK1 and NLK (Nemo-like kinase), which 
can antagonize the canonical Wnt pathway by regulating LEF1/TCF transcriptional 
factors (174).   
DKK-1 is a secreted antagonist of Wnt signaling that binds with high affinity to LRP6 
and LRP5 and this binding is essential for DKK-1 inhibition of Wnt signaling (175-
177). This interaction between DKK-1 and LRP6 has been suggested to result in an 
internalization and degradation of LRP6, thereby rendering the cells less responsive to 
Wnt signaling. Ultimately, the diverse biological roles for DKK-1 rely on its ability to 
inhibit β-catenin accumulation caused by activated Wnt signaling (178-180). 
Importantly, the Wnt signaling pathway stimulates DKK-1 expression as a negative 
feedback control mechanism for its activity (175). Also, GCs induce the transcription of 
DKK-1 through binding of GR to a GREs in the DKK-1 promoter (Paper IV) and 
cause GCs-mediated inhibition of Wnt dependent transcription and decrease of β-
catenin levels (109, 181-184). Treatment of cells with anti-DKK-1 antibodies have 
been demonstrated to partially suppress the GC-dependent inhibition of Wnt-signaling 
(182). In addition, liganded GR have been shown to represses cyclin D1 expression by 
directly targeting the Tcf/β -catenin complex (185). Taken together, GCs can inhibit the 
activity of Wnt-signaling at multiple levels. 
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3 AIMS OF RESEARCH 
 
Although GCs have been widely used since the late 1940s to treat inflammatory 
disorders, the molecular mechanisms responsible for their anti-inflammatory activity 
are still not completely resolved. This thesis contains studies (Paper I-IV) highlighting 
GR-cross talk abilities with other signaling pathways, including the two NF-κB 
pathways, the MAPK pathways and canonical Wnt signaling pathway. These pathways 
have either been described in pathology of inflammatory disorders or implicated as 
contributory for the adverse effects observed with GC therapy. In many cases, reported 
here and elsewhere, the use of GR mutants as investigative tools has been proven to be 
fruitful for the purpose of studying GC-cross-talk functions. More specifically, the aims 
of this thesis include: 
 
- To investigate the transcriptional activation mechanism by which GCs induce 
expression of the MAPK inhibitor, MKP-1 (Paper I).  
- To study GC crosstalk with canonical NF-κB activity and comparing the 
ability of wild-type versus mutant GR to transrepress NF-κB activated by 
different pro-inflammatory stimuli (Paper II). 
- To study GC-regulation of the non-canonical NF-κB pathway in an 
endogenous context and, with the use of GR mutants, determine what 
functions of GR that might be relevant for this regulation (Paper III). 
- To study the relevance of GC-induction of DKK-1 for neuronal progenitor 
cell (NPC) proliferation and differentiation and to study GR-binding to the 
DKK-1 gene (Paper IV). 
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4 RESULTS AND DISCUSSION 
 
4.1 PAPER I  
 
A large body of evidence supports an anti-inflammatory role for MKP-1, the prototype 
inhibitor of the MAPKs JNK, p38 and ERK1/2. GCs have been shown to stimulate 
expression of MKP-1 in a variety of cells and in absence of MKP-1, either by knock-
out or siRNA knock-down, GCs have partially impaired anti-inflammatory responses. 
Thus, the overall anti-inflammatory effects of GCs may, in addition to transcriptional 
repression of NF-κB, also involve GC-stimulation of inhibitory gene products e.g. 
MKP-1. Furthermore, since some dissociated GCs and transactivation-deficient GR 
mutants that are unable to operate through GREs still induce expression of MKP-1, 
transactivation of this gene by GR has been speculated to involve GRE-independent 
mechanisms. 
To study the transcriptional activation mechanism by which GCs induce MKP-1 
expression we first sought to confirm GR binding to the MKP-1 gene. Using a 
chromatin immunprecipitation (ChIP) scanning assay covering the proximal 3kb of the 
MKP-1 promoter, we demonstrated agonist-bound GR to bind to a single region 
approximately -1.4kb upstream from the transcription initiation site. Interestingly, so 
did the GR DBD mutant GRLS7 as well, which neither binds to nor transactivates GRE-
containing genes. Thus, we speculated that the GC-responsive region would be located 
in proximity to the binding site located at -1.4kb of the MKP-1 promoter. Indeed, 5’ 
promoter deletions of the 3kb MKP-1 promoter plasmid constructs had no effects on 
GC-responsiveness until position -1380bp while deletions beyond this point resulted in 
a loss of GC-responsiveness. A minimal GC-responsive fragment between position -
1380 and -1266 was identified. Sequence analysis of this 114bp fragment did not reveal 
any GRE-like sequences in this fragment but did however identify a binding site for 
C/EBP that was highly conserved among species. Using EMSA we confirmed that the 
protein complex formed on the 114bp minimal GC-responsive region included C/EBP. 
ChIP assay further revealed the concomitant binding of C/EBP and GR to the same 
region in the MKP-1 promoter. Importantly, GC-responsiveness of MKP-1 was 
significantly impaired when the C/EBP site was subjected to point mutations. Taken 
together, these results demonstrate that agonist-bound GR induces the expression of 
MKP-1 trough a positive tethering interaction involving promoter-bound C/EBP at a 
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C/EBP-binding site located -1.4kb upstream of the transcription start site, without the 
GR itself contacting the DNA (see also below).  
Since our published study in 2008, two later papers describing a similar GC regulation 
of MKP-1 have appeared (45, 186). Both studies provide interesting additions to the 
GC regulation of MKP-1. In the first study a longer stretch of the MKP-1 promoter 
(4.8kb) is used in promoter deletions studies (45). Deletions from -4834 to -2726 
impaired but did not eliminate the GC-response. A second drop in GC-response was 
observed on deletions between -1495 and -1095, which is similarly observed in our 
study. This suggests that that at least two regions in the MKP-1 promoter contribute to 
MKP-1 gene expression. In the second study, p300 was shown to be a necessary 
transcriptional co-activator for GR-regulated MKP-1 gene transcription (186). In line 
with our results, both these studies confirmed GR binding to the -1.4kb region by ChIP 
assay. In contrast to our study however, in silico analysis in both these studies indicated 
a GR binding site between positions -1337 and -1323 matching a loose consensus 
sequence XGXACXxxxXGTXCX. This site was not recognized as a GR binding site in 
our sequence analysis even at very low stringency settings of the sequence analysis 
tools we used. In one of the studies, Tchen et al. isolated a 130bp minimal GC-
responsive region between positions -1366 to -1237, which overlaps significantly with 
the 114bp minimal promoter construct found in our study (-1380 to 1266) (45). In Hela 
cells, mutations made in this context of the putative GRE resulted in impairment of the 
GC response, whereas mutations of the C/EBP-site had no effect on GC-responsiveness 
of this construct. In contrast to the situation in Hela cells, we observed that mutation of 
the C/EBP-site resulted in a significant decrease of GC-responsiveness in A549 cells. 
Furthermore, in our experiments we demonstrated that when a labeled consensus GRE-
sequence was incubated with recombinant GR DBD, this DNA-protein complex was 
not competed with an excess of our GC-responsive 114bp fragment, arguing against a 
direct GR binding to this part of the MKP-1 promoter. In contrast, using 
dexamethasone-treated nuclear extract from Hela cells incubated with a consensus 
GRE sequence, Tchen et al observed a relative, but not complete competition for GR-
binding with an excess of their 130bp GC-responsive MKP-1 fragment (45). Thus, 
Tchen et al suggested MKP-1 expression by GCs to be independent of C/EBP activity 
and to involve a direct binding of GR to MKP-1, contradictory to what we observed in 
our study. The reason for the differences is unclear but may relate to the use of different 
cells for the respective studies. 
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Supporting our suggestion of a tethering mechanism between GR and C/EBP, we 
demonstrated that in a native chromatin context the GRLS7 which does not bind to a 
classical GRE still is able to bind and induce MKP-1 expression.  
In summary, the discovery of GC-stimulation of MKP-1 involving GR-tethering with 
promoter-bound C/EBP (paper I), the possibility of additional regions (45) and 
additional transcription factors (187) being important for the GC-responsiveness and a 
hormone-dependent recruitment of certain co-activators (186) provides an increased 
understanding about the mechanisms behind GC-induced MKP-1 expression that could 
provide insights into new therapeutic approaches against inflammatory conditions. 
Interestingly, down-regulation of both C/EBPβ (188, 189) and MKP-1 (164) has been 
implicated separately in the GC-resistance of lung conditions such as asthma and 
chronic obstructive pulmonary disorder. 
 
 
4.2 PAPER II - III 
 
GR targets activated p65/p50 by various transcriptional repression mechanisms that 
inhibit gene expression of pro-inflammatory mediators regulated by the canonical NF-
κB signaling pathway. The activation of canonical NF-κB signaling by multiple 
inflammatory stimuli, including TNFα and TPA, is inhibited by GCs. 
To study if inflammatory cues might influence the ability of GCs to inhibit canonical 
NF-κB, we used a GR DBD mutant, GRR488Q, stably expressed in HEK293 cells to 
study aspects of this inhibition. We observed that while GRR488Q inhibited TNFα-
activated NF-κB, the GRR488Q was not capable of inhibiting NF-κB activated by TPA. 
The wild-type GR however, repressed NF-κB activity in both cases. Interestingly, the 
ability of GRR488Q to repress TPA-stimulated NF-κB activity was restored when TPA-
activated ERK1/2 was blocked either using a dominant negative MEK-1 mutant or the 
chemical inhibitor ERK-inhibitor U0126. In contrast to the wild-type GR, the GRR488Q 
did not induce expression of MKP-1. However, the differential ability by the wild-type 
and mutant GR to induce MKP-1 expression was not found to be relevant for their 
dissimilar ability to repress NF-κB activity in these cells. This concluded that GR 
repression of NF-κB in these cells occur independently of MKP-1 induction by GCs. 
Thus, our study provides evidence demonstrating that GR-mediated repression of 
activated NF-κB requires separate functions of the GR and, importantly, that repression 
   29 
of canonical NF-κB signaling by GR may not only depend on the particular gene and 
cell context, but can also depend on what signaling pathway is employed to activate 
NF-κB. This is in line with previous results from the laboratory of Glass and co-
workers, who showed that the GR only represses NF-κB dependent target genes 
following activation by the TLR4 and TLR9 but not following NF-κB activation by 
TLR3 (54). In this case, the different signal transduction pathways used to activate NF-
κB resulted in differential co-activator utilization by NF-κB, which constituted the basis 
for the differential GC response of NF-κB target genes. In summary, this highlights the 
complexity and diversity in the mechanisms involved in GR repression of the canonical 
NF-κB pathway. 
 
With regards to GC interaction with the non-canonical NF-κB pathway, little is known. 
A recent study observed that co-treatment with dexamethasone potentiated the ability 
of 1,25(OH)vitamin-D3 to decrease the de novo expression of RelB protein in dendritic 
cells (190). Although this could indeed be one of the ways in which GCs limit the 
activity of non-canonical NF-κB signaling, no studies have yet demonstrated a 
capability of GCs to inhibit ReB/p52 driven transcription or a physical interaction 
between GR and RelB. In paper III, we demonstrate that agonist-bound GR can 
repress gene transcription stimulated by RelB/p52 in both endogenous and ectopic 
expression conditions. LTβR stimulation of mouse embryonal fibroblast (MEF) cells 
lacking p65, but not RelB, resulted in the increase of NF-κB reporter gene expression, 
which is in line of it being a known activator of the non-canonical NF-κB pathway. 
This LTβR activated RelB-dependent expression of the NF-κB reporter gene was 
inhibited by co-treatment with dexamethasone. Furthermore, in COS7 cells transiently 
co-transfected with expression plasmids for GR, RelB and p52, the GR 
transcriptionally inhibited RelB/p52 and physically interacted with the RelB subunit in 
response to GC treatment. Finally, wild-type GR, stably expressed in HEK293 cells, 
inhibited reporter gene expression driven by RelB/p52 whereas repression of RelB/p52 
activity by GR DBD mutants GRR488Q and GRLS7 was slightly impaired, which would 
suggests the GR DBD to be involved in the repression of non-canonical NF-κB 
signaling by GR. To our knowledge, this is the first evidence demonstrating an ability 
of GCs to repress the transcriptional activity of the non-canonical NF-κB signaling 
pathway and an ability of GR to interact with RelB in a hormone-dependent manner. In 
light of studies implicating a deregulated non-canonical pathway in inflammatory 
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disorders (129), the significance of the ability of GR to down-regulate RelB/p52 
transcriptional activity for the overall inflammatory effects by GCs is interesting, but 
remains to be further explored. 
Blocking defective activation of NF-κB by either targeting the classical and/or the 
alternative pathway may be therapeutically beneficial for many inflammatory diseases 
and hematopoietic malignancies (125, 129). The classical NF-κB pathway signals the 
production of pro-inflammatory cytokines and inflammatory mediators via the activity 
of p65/p50 heterodimers, whereas the alternative NF-κB pathway regulates genes 
important for lymphoid organ development and B lymphocyte maturation and survival 
via RelB/p52 heterodimers. Interrelationship studies between the NF-κB pathways 
demonstrate that a deletion of RelB in mice results in multi-organ inflammation and 
increased production of TNFα (191). This could imply that the NF-κB pathways act 
antagonistically against each other and a mechanism for a competitive interference 
binding with p65 by RelB has been proposed as a way of which RelB can regulate the 
production of TNFα (192). Moreover, studies have shown that p100 can function as an 
IκB and bind to canonical NF-κB heterodimers preventing their nuclear translocation 
(193, 194). Conversely, classical NF-κB signaling has been shown to inhibit the non-
canonical pathway. A recent study demonstrated that classical NF-κB activation via 
TNFα stimulation negatively regulates alternative NF-κB dependent expression of the 
homeostatic chemokine CXCL12 in human umbilical vein endothelial cells (130). 
Also, RelB and p100 are inducible target genes of p65/p50 and have been implicated to 
serve as a feedback mechanism to limit both an undue p65/p50 and RelB/p52 driven 
gene transcription (195). Taking these observations together, the alternative NF-κB 
pathway has been branded as a balancing anti-inflammatory control pathway to the 
classical NF-κB pathway. However, this view may not fully explain the relationship 
between these two pathways. Studies show that certain inducers of NF-κB activity give 
rise to two waves of activation: first of the classical NF-κB pathway and then later 
followed by the alternative pathway to induce the expression of shared target genes. For 
instance, a recent study showed that expression of the polymeric immunoglobulin 
receptor (pIgR) in intestinal epithelial cells was regulated by both the classical and the 
alternative NF-κB pathway, while the induction of pro-inflammatory genes such as IL-
8 required only p65 (196). Also, the alternative NF-κB signaling pathway was shown to 
be vital to mount a proper immune response against lymphocytic choriomeningitis 
virus (LCMV) in mice (197, 198). Thus seemingly, highly dependent on the cell type 
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and the nature of the stimulus, the classical and alternative NF-κB pathways can control 
target genes independently of each other, in synergy or antagonistically.  
Recently various chronic inflammatory diseases, in particular those chiefly 
characterized by an abnormal B-cell activity and autoantibody production such as 
rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, and Sjögrens 
syndrome, have been proposed to be driven by an excess activation of the alternative 
NF-κB pathway (199-203). BAFF, a potent stimulator of the alternative NF-κB 
pathway, has been found in elevated levels in the sera of patients suffering various 
autoimmune conditions and neutralizing agents targeting BAFF has shown to have 
positive outcomes in clinical trials correlating to a depletion of mature peripheral B-cell 
subsets (204, 205). Moreover, patients with particular infectious diseases connected to 
autoimmune conditions (e.g. EBV, HPC, HIV) have elevated levels of selective 
inducers of the alternative NF-κB pathway, such as BAFF and APRIL, in their sera 
(200, 206). Additionally, many reports describe the survival of B-cells to be dependent 
on the up-regulation of anti-apoptotic factors (e.g. Bcl-2, Bcl-X) by the alternative NF-
κB pathway (207). In line with this observation, the alternative NF-κB pathway has 
been implicated in the apoptotic resistance and uncontrolled activity of pre B 
lymphoma, myeloma, Hodgkin’s lymphoma and chronic lymphocytic leukemia (CLL) 
cells (208). Interestingly, GCs induce cell cycle arrest and apoptosis of lymphoid cells 
and constitute an important part among the chemotherapeutic regimens for the 
treatment of many of the lymphoid malignancies where deregulated non-canonical NF-
κB signaling has been implicated (209, 210). A possible cross-talk between GCs and 
non-canonical NF-κB signaling in lymphoid malignant cells might exist but has not yet 
been demonstrated. 
 
4.3 PAPER IV 
 
DKK-1 is a secreted protein that inhibits the Wnt/ β-catenin signaling pathway, which 
is a major signaling cascade in various cells. Recent evidence has suggested that 
deregulation of DKK-1 expression is causally related to the process of 
neurodegeneration in a number of disorders of the central nervous system, including 
Alzheimers disease (211), brain ischemia (212) and temporal lobe epilepsy (32). 
Targeting the increased expression of DKK-1 and restoring Wnt-signaling has been 
suggested for the treatment of these neurodegenerative disorders (213). Also, DKK-1 
regulates bone development and elevated DKK-1 expression has been implicated in 
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causing bone resorption and erosive arthritis in multiple myeloma (214-216). GCs have 
been shown to stimulate the expression of DKK-1 in several cells most notably in 
osteoblasts (109, 182-184, 217) and, as recently discovered, in hippocampal neurons 
(218).  
In paper IV, we demonstrated that GC-treatment of human neuronal progenitor cells 
(hNPCs) markedly decreased proliferation and neuronal differentiation while it 
promoted glia cell formation. Analysis of pathway-specific genes revealed that Dex 
induced DKK-1 in hNPCs. Dex- or DKK-1-treated hNPCs showed reduced 
transcriptional levels of the two canonical Wnt target genes cyclin D1 and inhibitor of 
DNA binding 2 (ID2). Furthermore, a putative GRE in regulatory promoter region of 
DKK-1 has been suggested by sequence analysis and using ChIP assay we 
demonstrated that GR binds to this GRE in the DKK-1 promoter and stimulates 
expression of DKK-1 in a hormone-dependent manner. Taken together, these findings 
show that GCs reduce proliferation and interfere with differentiation of hNPCs via 
inhibition of the canonical Wnt signaling pathway. Other reports support the 
observation made in Paper IV and show that both NPCs and immature neurons in the 
hippocampus are sensitive to the pro-apoptotic actions of GCs. For instance, induction 
of DKK-1 by GCs was demonstrated to cause stress-induced hippocampal damage 
(218) and is suggested to be involved in hippocampal athrophy observed in depressed 
patients. Also, the stimulation of DKK-1 by GCs in osteoblasts has been implicated as a 
mechanism for GC-induced osteoporosis. A recent study demonstrated that silencing 
DKK-1 expression rescued dexamethasone-induced suppression of primary human 
osteoblast differentiation (109). Importantly, clinical agents that antagonizes DKK-1 
and rescues canonical Wnt signaling could therefore potentially attenuate adverse 
effects observed with GC therapy, such as hippocampal damage and osteoporosis. 
Both canonical and non-canonical Wnt signaling has been implicated in inflammatory 
disease. For instance, β-catenin levels in macrophage-like microglia are elevated in 
Alzheimer’s disease associated with chronic neuroinflammation and the canonical 
Wnt3a ligand induces the expression of pro-inflammatory cytokines including 
interleukin (IL)-6, IL-12 and TNFα (219, 220). Furthermore, Wnt5a, a representative 
ligand for the non-canonical Wnt pathway, has recently been implicated in both 
inflammatory response and disease. The expression of Wnt5a and frizzled 5, a possible 
receptor for Wnt5a, is enhanced in synoviocytes of rheumatoid arthritis (221) and the 
blockade of Wnt5a signaling inhibits synoviocyte activation (222). Wnt5a has also 
been detected in the sera of patients with severe sepsis (173). These reports suggest a 
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role for Wnt signaling pathways in the pathology of various inflammatory disease 
conditions and thus, might be candidate molecular targets for treatment by anti-
inflammatory drugs e.g. GC therapy. 
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5 CONCLUDING REMARKS AND FUTURE 
PERSPECTIVES 
 
The MAPK signaling pathways, the canonical and non-canonical NF-κB pathways, and 
the canonical and non-canonical Wnt pathways have all been implicated in 
inflammatory diseases. GCs, potent anti-inflammatory hormones, inhibit these 
signaling pathways in part by stimulating expression of their archetypical inhibitors 
(e.g. IκBα, MKP-1 and DKK-1) and in the case for canonical NF-κB signaling, also 
through several transrepression mechanisms involving an inhibitory GR interaction 
with activated p65/p50. This thesis covers aspects of molecular cross-talk between GR 
and these signaling pathways.  
The relevance of GCs capability to transactivate anti-inflammatory genes for their 
overall anti-inflammatory effects of GCs is still debated (see above). Animal knock-out 
models of GC target genes (e.g. IL-10-/- and MKP-1-/-) exist to study this purpose. 
However, the mechanisms by which GCs induce expression of some of these genes 
remain either elusive or unaddressed. In paper I, we demonstrate that the 
transcriptional activation mechanism of MAPK-inhibitor MKP-1 by GCs is 
independent of a direct DNA-binding by GR, but instead involves a positive tethering 
between a promoter-bound C/EBP and the GR around an evolutionary conserved 
region -1.4kb upstream of the transcription start site. Non-classical transcriptional 
activation mechanisms as the one described in Paper I, would explain why some 
dissociated GCs and GR mutants that are transcriptionally inactive at GRE-containing 
genes still can induce a subset of GC target genes such as MKP-1. In addition to our 
study, other studies have expanded on the mechanisms underlying GR-regulation of the 
MKP-1 and have provided interesting new characteristics for GC-induction of this 
gene. Therefore, GC-regulation of genes that are suggested to be transactivated by GR 
through non-classical mechanisms, e.g. MKP-1, IL-10 and IκBα (223) merits more 
studies and could provide important clues about the mechanisms behind transcriptional 
regulation by GCs. Ultimately, it would be interesting to utilize genome-wide profiling 
methods to further investigate transcriptional regulation of GC target genes by 
dissociated GR agonists and GR mutants, such as GRLS7. This could provide important 
information about the proportion and relationship of GC-target genes that are regulated 
through direct and indirect mechanisms.  
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In papers I-III GR mutants are used as investigative tools. Our results in using 
GRR488Q showed that it was unable to repress NF-κB activity following stimulation by 
the phorbol ester TPA, but did so following activation by TNFα, while wild-type GR 
repressed NF-κB in both cases (paper II). This seemed to relate to the differential 
ability to activate of ERK1/2 by TPA and TNFα in the HEK293 cells. Blocking 
ERK1/2 enhanced the ability of a GRR488Q to inhibit TPA-stimulated NF-κB activity. 
These results stress that the nature of the inducer of NF-κB activity may have profound 
effects on the mechanism by which the GR represses NF-κB. This is in line with 
previous observations (54) and provides an additional layer of complexity to cross-talk 
between NF-κB and GR that is worth to further investigate. Notably, GR activity may 
be impaired by both p38 MAPK (165, 224, 225) and JNK (162, 226, 227) and GR 
mutants, due to their mutations, might be more susceptible to post-translational 
modifications. More in depth studies investigating if GR monomers are more sensitive 
to post-translational modifications could be valuable to investigate, with the use of GR 
dimerization mutants and clinically aspiring monomer inducing GC agonists. 
The study of GC-crosstalk with NF-κB has mainly involved the canonical or “classical” 
NF-κB pathway due to its involvement in the inflammatory response and its 
deregulation in inflammatory disorders. In paper III we demonstrate that GCs extend 
their inhibitory actions to the non-canonical NF-κB pathway. This is to the author’s 
best knowledge the first time a cross-talk between non-canonical NF-κB pathway and 
GC signaling has been described. Thus, a broad range of future studies could provide 
more knowledge into this area of research. For instance, if a good model gene for the 
non-canonical pathway could be found that is repressed by GCs, as is the case for 
COX-2 and IL-8 for the canonical pathway, GR transrepression mechanisms at non-
canonical genes could be studied in more detail. Furthermore, the implications of cross-
talk between GC-signaling and non-canonical NF-κB activity in inflammatory disease 
and hematopoietic malignancies remain to be investigated. This should be further 
explored in e.g. B-cells where the cytokine BAFF signals purely through the non-
canonical NF-κB pathway. Furthermore, the effect of GCs on a deregulated non-
canonical NF-κB pathway and excessive BAFF production in animal models of 
inflammatory disease could provide important insights into the anti-inflammatory 
actions of GCs. Interestingly, two recent studies has demonstrated that dexamethasone 
inhibits BAFF expression in synoviocytes from patients with rheumatoid arthritis (228) 
and in patients with immune thrombocytopenia (229), without explicitly connecting 
this to an ability by GCs to inhibit non-canonical RelB/p52 activity. Furthermore, 
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elevated BAFF levels have been shown to counter the pro-apoptotic effects of GCs and 
protect myeloma cells from apoptosis (230). Moreover, it would be interesting to 
compare the effects of particular dissociated GCs on the ability of GC-crosstalk with 
the non-canonical NF-κB signaling pathway, in addition to the canonical pathway. The 
effects of these dissociated GCs on both canonical and non-canonical NF-κB target 
genes could be analyzed on a genome wide scale using high-throughput gene array 
platforms, which could in turn provide clues about the possible in vivo effectiveness of 
future compounds and give a powerful reflection of their dissociative nature with 
regards to transcriptional regulation. 
 
Because of the ubiquitous tissue distribution of GR and the wide variety of genes under 
GC-control, prolonged GC therapy of inflammatory disorders is often associated with 
unwanted side effects. For instance, GCs affect the development, survival and death of 
neurons and excessive levels GCs have been linked to neurodegeneration of the 
hippocampus. Also, GC therapy is often predictably accompanied by GC-induced 
destruction of bone tissue. Interestingly, both these adverse effects has been suggested 
to be mediated by GC-inhibition of canonical Wnt signaling in NPCs and osteoblasts 
respectively, through the transcriptional activation of the soluble Wnt signaling 
inhibitor DKK-1 by GCs (109, 218). In paper IV we demonstrate that GCs induce 
expression of DKK-1, by a direct binding of GR to the GRE in the DKK-1 promoter. 
This inhibits Wnt-dependent transactivation of Cyclin D1 and ID2 and halts 
proliferation and differentiation of NPCs. Thus, antibodies targeting DKK-1 could be 
valuable in the management of GC-induced osteoporosis and manifestations of 
depression and cognitive disorders caused by HPA-axis hyperactivity or exogenous 
GCs. Importantly, since GC-activation of DKK-1 expression requires a direct DNA-
binding by GR to a functional GRE in the DKK-1 promoter, the use of dissociated GCs 
that do not activate GRE-containing genes might be warranted to limit GC effects on 
the Wnt signaling pathway. On the other hand, both the canonical and non-canonical 
Wnt pathways have recently been implicated in inflammatory disease. Here, the role of 
GC-crosstalk with Wnt signaling and the possible effects on inflammation still remains 
an unexplored area of research. The significance of GC up-regulation of DKK-1 and 
IL-10 for a deregulated Wnt signaling in inflammatory disease should be examined. 
GCs have been shown to inhibit TAK1 in other contexts (231) and may serve as a way 
by which GCs can inhibit both TLR-stimulated Wnt5a expression and Wnt5a signaling. 
Although no reports have studied a direct transcriptional repression of Wnt5a-activated 
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NFAT by GR, GR can inhibit NFAT DNA-binding activity in thymocytes by 
disrupting AP-1 and NFAT transcriptional partnership (232). Moreover, pro-
inflammatory target genes of Wnt5a include IL-1, IL-6 and COX2, which are 
negatively regulated by GCs when they are activated by other signaling pathways, 
including NF-κB and MAPK signaling pathways (87 and paper II).   
 
Ultimately, the use of available high-trough put based systems in GC-target tissues to 
evaluate the dissociated qualities of selective GC agonist and to predict therapeutic 
index of these compounds is bound to be more fruitful than the use of simple GRE 
reporter based system and a selection of biomarker genes in limited number of cell 
types. However, a complete separation of transrepression and transactivation of GR 
may be difficult to achieve due the multiple mechanisms described for transcriptional 
regulation by GR (e.g. DKK-1, which is up-regulated by GR through direct GRE-
binding and MKP-1, which is up-regulated by GR through positive tethering) and could 
possibly be undesirable because of a potentially critical interdependency between these 
two regulatory processes for GC-suppression of inflammatory responses (e.g. MKP-1 
stimulation and NF-κB-repression) (Fig. 3). Nevertheless, dissociated GR agonists hold 
significant promise as anti-inflammatory drugs and could potentially provide a safer 
and more effective treatment option for some inflammatory disorders that today require 
treatment with non-dissociated GC equivalents, although ultimately, a single 
dissociated GR ligand might not be useful for all inflammatory disorders considering 
that gene-specific mechanisms and a variety in cross-talk mechanisms may be involved 
in inflammatory pathologies and side effects in different tissues. 
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